Overview of Gastroprotectant Drugs
Treatment and Prevention of Peptic Ulcer Disease
Gastroprotectant drugs are essential in the treatment and prevention of peptic ulcer disease and its associated complications. A recent study conducted in the UK sheds light on the efficacy of various gastroprotectants in different clinical contexts.
Understanding Peptic Ulcer Disease
Peptic ulcer disease encompasses ulcers in both the stomach, known as peptic ulcers, and the upper intestine, referred to as duodenal ulcers. This condition can lead to serious complications if left untreated, such as gastrointestinal bleeding, perforation, and obstruction.
Causes of Peptic Ulcer Disease
The primary contributors to peptic ulcer disease include infection with Helicobacter pylori and the use of non-steroidal anti-inflammatory drugs (NSAIDs), including ibuprofen.
Types of Gastroprotectant Drugs
The three main classes of gastroprotectant drugs that play a role in the prevention and treatment of peptic ulcer disease and its complications are:
1. Proton Pump Inhibitors (PPIs)
2. Prostaglandin Analogues
3. Histamine-2 Receptor Antagonists
Despite their importance, there is limited evidence regarding the most effective gastroprotectant in various clinical scenarios.
Recent Research Findings
Study Overview
Researchers from the Nuffield Department of Population Health in the UK conducted a meta-analysis to explore the performance of different gastroprotectant classes across various clinical situations. Their findings were published in The Lancet Gastroenterology and Hepatology.
Methodology
The researchers selected studies that randomly assigned participants to receive either a gastroprotectant drug or a placebo/another gastroprotectant. The analysis included three types of studies:
1. Prevention trials
2. Treatment or healing trials
3. Upper gastrointestinal bleeding treatment trials
Key Results
The analysis revealed that the use of any gastroprotectant drug compared to a placebo significantly reduced the risk of developing endoscopically diagnosed ulcers, symptomatic ulcers, or complications.
Effectiveness of Gastroprotectants
– In prevention trials, proton pump inhibitors were found to be the most effective for preventing duodenal ulcers, while prostaglandin analogues excelled at preventing gastric ulcers.
– For symptomatic ulcers in healing trials, proton pump inhibitors also demonstrated greater effectiveness. However, there was insufficient data to compare the treatment efficacy of gastric versus duodenal ulcers.
– In upper gastrointestinal bleeding trials, proton pump inhibitors outperformed both prostaglandin analogues and histamine-2 receptor antagonists. Evidence regarding complications from peptic ulcer disease, aside from upper gastrointestinal bleeding, remains limited.
Conclusion
Overall, proton pump inhibitors are shown to be more effective than other gastroprotectant drugs in both the treatment and prevention of peptic ulcer disease and its complications. Prostaglandin analogues are particularly effective for preventing gastric ulcers. Future research is necessary to evaluate the safety profiles of each gastroprotectant and their impact on complications beyond bleeding.
Written by Jessica Caporuscio, PharmD
Reference: Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018.